|
|
||||||||




* Committee on Immunology and
Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, IL 60637;
Division of Gastroenterology-Hepatology, Department of Internal Medicine, Tufts New England Medical Center, Boston, MA 02111; and
Department of Inflammation, Amgen Inc., Thousand Oaks, CA 91320
The T cell costimulatory molecule ICOS regulates Th2 effector function in allergic airway disease. Recently, several studies with ICOS–/– mice have also demonstrated a role for ICOS in Th2 differentiation. To determine the effects of ICOS on the early immune response, we investigated augmenting ICOS costimulation in a Th2-mediated immune response to Schistosoma mansoni Ags. We found that augmenting ICOS costimulation with B7RP-1-Fc increased the accumulation of T and B cells in the draining lymph nodes postimmunization. Interestingly, the increased numbers were due in part to increased migration of undivided Ag-specific TCR transgenic T cells and surprisingly B cells, as well as non-TCR transgenic T cells. B7RP-1-Fc also increased the levels of the chemokines CCL21 and CXCL13 in the draining lymph node, suggesting ICOS costimulation contributes to migration by direct or indirect effects on dendritic cells, stromal cells and high endothelial venules. Further, the effects of B7RP-1-Fc were not dependent on immunization. Our data support a model in which ICOS costimulation augments the pool of lymphocytes in the draining lymph nodes, leading to an increase in the frequency of potentially reactive T and B cells.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by National Institute of Health Grants R01 AI50180 (A.I.S.) and K08 AI059105 (R.A.S.) and a fellowship from the American Lung Association of Metropolitan Chicago (R.A.S.). M.D.A. was supported by a fellowship from the Howard Hughes Medical Institute undergraduate research program. The University of Chicago Flow Facility was supported in part by the University of Chicago Cancer Center National Institutes of Health Grant CA14559.
2 A.G.T. and R.A.S. contributed equally and should be considered co-first authors.
3 Address correspondence and reprint requests to Dr. Rebecca A. Shilling, University of Chicago, MC6076, M658, 5841 South Maryland Avenue, Chicago, IL 60637. E-mail address: rshillin{at}medicine.bsd.uchicago.edu
4 Abbreviations used in this paper: HFc, Human-Fc; DLN, draining lymph node; SEA, soluble egg antigen; LN, lymph node; Tg+, DO11.10 TCR transgenic T cell.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |